Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity (Q43189281)

15 November 2017

title

Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity (English)

1 reference

15 November 2017

1 reference

1 reference

Gitte Pedersen

1

1 reference

15 November 2017

Jørn Brynskov

series ordinal

2

1 reference

15 November 2017

language of work or name

English

0 references

publication date

19 January 2010

1 reference

The American Journal of Gastroenterology

15 November 2017

published in

1 reference

15 November 2017

volume

105

1 reference

15 November 2017

issue

7

1 reference

15 November 2017

page(s)

1595-1603

1 reference

PPARgamma as a new therapeutic target in inflammatory bowel diseases

15 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Differential expression, distribution, and function of PPAR-gamma in the proximal and distal colon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

4-Hydroxydocosahexaenoic acid, a potent peroxisome proliferator-activated receptor gamma agonist alleviates the symptoms of DSS-induced colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

The PPARgamma agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Will 2008 mark the start of a new clinical trial era in gastroenterology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

A simple method to establish short-term cultures of normal human colonic epithelial cells from endoscopic biopsy specimens. Comparison of isolation methods, assessment of viability and metabolic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Controversy: PPARgamma as a target for treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Superoxide production and expression of NAD(P)H oxidases by transformed and primary human colonic epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Regulation of epithelial-mesenchymal IL-1 signaling by PPARbeta/delta is essential for skin homeostasis and wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Tumor necrosis factor-alpha inhibits peroxisome proliferator-activated receptor gamma activity at a posttranslational level in hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Interferon-gamma-induced regulation of peroxisome proliferator-activated receptor gamma and STATs in adipocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Increased concentrations of interleukin 1 beta, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.749

21 January 2018

Identifiers

DOI

10.1038/AJG.2009.749

1 reference

15 November 2017

1 reference